Liquid biopsy companies Illumina and Guardant have agreed to end their intellectual property litigation and work together on cancer research.
Instead of continuing to fight in court, Guardant and Illumina will extend their “long-standing commercial relationship” and share samples to cancer research, Guardant announced on 1 August
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?